i-79b in NHL (Non-Hodgkin's lymphoma) also at ASCO (May 31) should provide another leg to Roche's existing growth and protection strategies for the Rituxan franchise (which currently include Gazyva replacing Rituxan; BCL-2 use on-top of Rituxan) and Kadcyla data in 1st line Breast Cancer from the MARIA